ARVO Meeting Yields Positive Results for Paradigm

  Paradigm Medical Industries, Inc. (PINKSHEETS: PDMI) announced today that attendance at the recent Association for Research in Vision and Ophthalmology (ARVO) meeting, held in Ft. Lauderdale, Florida from May 2-5, 2010 exceeded expectations. "The ARVO meeting was an excellent opportunity for Paradigm to continue to develop cooperative professional relationships and introduce the Paramax, a new device currently under FDA review pursuant to a 510(k) application. The meeting also resulted in several new product development opportunities," said Stephen Davis, the Company's President and CEO.

The ARVO Meeting was attended by Mr. Davis and Julio Maximo, the Company's Vice President of Operations. Although the meeting format is not generally considered a "selling" meeting, Paradigm actually sold over $125,000 of its equipment. The Company also received many leads that might result in future sales of its equipment.

During the time spent in Ft. Lauderdale, Mr. Davis met with new product developers, development engineers, financial partners and many physicians who represent leadership roles in the ophthalmic industry. "I am pleased with the results of the time spent with companies and individuals at the meeting, but I am more pleased with the renewed interest in our current and new products. This meeting will definitely help put Paradigm Medical back on the map," added Mr. Davis.

About Paradigm Medical Industries, Inc.

Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes ophthalmic diagnostic instruments and related products for early detection of glaucoma and other eye disorders. The Company's primary objective is to capture a niche market within the glaucoma and ultrasound microscopy fields. The Company markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States and internationally.

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

Contact: Stephen L. Davis President and Chief Executive Officer 801-977-8970 www.paradigm-medical.com